BSX

Miami International Holdings Announces SEC Publishes Notice of Form 1 Application for New Miami-Based MIAX Sapphire Options Exchange

Retrieved on: 
Tuesday, October 17, 2023
Emerald, Maker, Security (finance), Taker, Form 1 Planet, MIH, Bermuda Stock Exchange, BSX, Strategic planning, Minneapolis Grain Exchange, Business development

PRINCETON, N.J., Oct. 17, 2023 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that a notice of its Form 1 application for its newest options exchange has been published by the Securities and Exchange Commission (SEC).

Key Points: 
  • PRINCETON, N.J., Oct. 17, 2023 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that a notice of its Form 1 application for its newest options exchange has been published by the Securities and Exchange Commission (SEC).
  • MIH filed the Form 1 application to register MIAX Sapphire as a national securities exchange operating both an electronic exchange and physical trading floor for U.S. options.
  • MIAX Sapphire will utilize Taker-Maker pricing and a Price-Time allocation model while leveraging existing MIAX-based technology and infrastructure, enabling existing MIAX Exchange members access to the new exchange with minimal additional technology efforts.
  • For more information on MIAX Sapphire, including key milestone dates, member on-boarding and technology requirements, please visit miaxglobal.com/markets/us-options/sapphire-options or contact MIAX Trading Operations at [email protected] .

Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results

Retrieved on: 
Monday, October 2, 2023
Webcast, News, NYSE, EDT, Boston Scientific, BSX, Cryptocurrency, Broadcasting, Management

MARLBOROUGH, Mass., Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT.

Key Points: 
  • MARLBOROUGH, Mass., Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT.
  • The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.
  • The company will issue a news release announcing financial results for the third quarter on October 26 prior to the conference call.
  • The replay will be available approximately one hour following the completion of the event.

CVS Health appoints Michael F. Mahoney to its Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Health informatics, University, Medical device, Diagnosis, Wake Forest University, BSX, Health, Endoscopy, The Advisory Board Company, Baxter International, Patient, Electrophysiology, Boston College, Johnson & Johnson, CVS Health, Boy, NYSE, Urology, Independent, Worldwide, Management, Nursing, Pharmaceutical industry, Boston Scientific

WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.

Key Points: 
  • WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.
  • "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch.
  • Mahoney became the CEO of Boston Scientific Corporation in 2012 and became Chairman of the company's Board of Directors in 2016.
  • "We're extremely pleased to have Mike join the Board," said Roger N. Farah, Independent Chair of the Board of CVS Health.

Miami International Holdings Announces that MGEX has Filed a Petition for Rehearing Following Court's Decision to Vacate SEC's Exemptive Order Related to SPIKES Volatility Index Futures

Retrieved on: 
Thursday, September 14, 2023
Emerald, Uncertainty, Chicago, SPY, MIH, VIX, MGEX, BSX, Commission, En banc, Bermuda Stock Exchange, Petition, Order, Court, Growth, Minneapolis Grain Exchange, Ecosystem, Financial adviser, Cryptocurrency, Security (finance)

The Order permits the listing of SPIKES Futures as a futures contract on MGEX, which serves as the exclusive market for this contract.

Key Points: 
  • The Order permits the listing of SPIKES Futures as a futures contract on MGEX, which serves as the exclusive market for this contract.
  • If the petition is denied, then the new date for the vacatur is three months after the end of the month in which such denial is issued.
  • If the petition is granted, then the Order would remain in effect until the Court hears the matter again and/or issues a new opinion.
  • Accordingly, the earliest date on which SPIKES Futures will be required to cease trading on MGEX is January 1, 2024.

Miami International Holdings Announces that MGEX has Filed a Petition for Rehearing Following Court's Decision to Vacate SEC's Exemptive Order Related to SPIKES Volatility Index Futures

Retrieved on: 
Thursday, September 14, 2023
Emerald, Uncertainty, Chicago, SPY, MIH, VIX, MGEX, BSX, Commission, En banc, Bermuda Stock Exchange, Petition, Order, Court, Growth, Minneapolis Grain Exchange, Ecosystem, Financial adviser, Cryptocurrency, Security (finance)

The Order permits the listing of SPIKES Futures as a futures contract on MGEX, which serves as the exclusive market for this contract.

Key Points: 
  • The Order permits the listing of SPIKES Futures as a futures contract on MGEX, which serves as the exclusive market for this contract.
  • If the petition is denied, then the new date for the vacatur is three months after the end of the month in which such denial is issued.
  • If the petition is granted, then the Order would remain in effect until the Court hears the matter again and/or issues a new opinion.
  • Accordingly, the earliest date on which SPIKES Futures will be required to cease trading on MGEX is January 1, 2024.

Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device

Retrieved on: 
Wednesday, September 6, 2023
Boston Scientific, BSX, Stroke, Food and Drug Administration, FLX, NVAF, Inflammation, NYSE, Thrombosis, Patient, Physician, Risk, Cardiology, LAAC, LAA, Food, Safety, Ventricular fibrillation, Medical imaging

MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. Designed to further advance the procedural performance and safety of the WATCHMAN technology, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, the device now features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Key Points: 
  • MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
  • The latest WATCHMAN FLX Pro device is enhanced with a coating designed to reduce device-related thrombus and enable faster, controlled healing and endothelization of the device surface.
  • The WATCHMAN FLX Pro device maintains key characteristics of the WATCHMAN FLX device, including the fully rounded design that enables physicians to safely enter, and maneuver within, the left atrial appendage.
  • The WATCHMAN FLX Pro device is currently being studied in the WATCHMAN FLX Pro CT study, a single-center premarket study using multiple imaging modalities to assess post-procedural device tissue coverage and the relationship, if any, to clinical outcomes.

Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results

Retrieved on: 
Tuesday, September 5, 2023
Webcast, BSX, NYSE, Boston Scientific, Management

MARLBOROUGH, Mass., Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between 8:30 a.m. and 1:00 p.m.

Key Points: 
  • MARLBOROUGH, Mass., Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between 8:30 a.m. and 1:00 p.m.
  • "We are looking forward to our 2023 Investor Day, where our leadership team will provide more insight into our current pipeline, near-term catalysts and our long-range financial goals."
  • The Investor Day meeting will be held in hybrid format, in person in Boston and online as a simultaneous webcast.
  • The company also announces that it will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023 before the market opens.

Boston Scientific Receives FDA Approval for the POLARx™ Cryoablation System

Retrieved on: 
Tuesday, August 8, 2023
Heart, Freedom, Pulmonary vein stenosis, Boston Scientific, BSX, Anatomy, CE marking, Medicines and Healthcare products Regulatory Agency, Food and Drug Administration, FACC, Clinical trial, Cryoablation, Cryotherapy, Banner University Medical Center Tucson, Heart Rhythm, Patient, Freezing, Physician, PMDA, AF, FDA, NYSE, Food, Safety, Medical imaging, Medical device, FHRS, MD, Electrophysiology

MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System. The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation (AF), features the POLARx FIT Cryoablation Balloon Catheter, a device with the unique capability of enabling two balloon sizes – 28 and 31mm – in one catheter.

Key Points: 
  • First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems
    MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System.
  • "The U.S. approval of the POLARx Cryoablation System, which has been used in more than 25,000 patients worldwide to date, marks an exciting advancement for the treatment of AF and a new era of cryoablation capabilities," said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
  • The POLARx Cryoablation System received CE Mark in February of 2020 and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval in October of 2021.
  • The POLARx FIT catheter received approval in Europe, Japan, Canada and other Asia Pacific markets in 2023.

Privia Health Announces Changes to Board of Directors

Retrieved on: 
Monday, July 31, 2023
UnitedHealth Group, Goldman, Bear Stearns, University, Boston Scientific, BSX, Arthur Andersen, Health, CAH, CHRO, Sale, Coca-Cola Enterprises, Cardinal Health, Goldman Sachs, UNH, Patient, Physician, Citigroup, HR, Lucent, Growth, Policy, Cornell University, NYSE, General Motors, Management, Nursing, Manulife

She previously served on Manulife’s Board of Directors from 2016 to 2018 and Perspecta, Inc.’s Board from 2017 to 2021.

Key Points: 
  • She previously served on Manulife’s Board of Directors from 2016 to 2018 and Perspecta, Inc.’s Board from 2017 to 2021.
  • “Privia Health is helping to transform the health care system by enabling physicians to practice more effectively and deliver better patient outcomes at lower cost.
  • “These changes continue the process of broadening the capabilities and expertise of our Board of Directors,” said David King, Chairman of the Privia Health Board of Directors.
  • In addition, on behalf of our entire board, we thank Jeff Bernstein for his important contributions to Privia Health during his time as a board member.”

Boston Scientific Announces Conference Call Discussing Second Quarter 2023 Results

Retrieved on: 
Wednesday, June 28, 2023
Webcast, News, NYSE, EDT, Boston Scientific, BSX, Cryptocurrency, Broadcasting, Management

MARLBOROUGH, Mass., June 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27, 2023 at 7:30 a.m. EDT.

Key Points: 
  • MARLBOROUGH, Mass., June 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27, 2023 at 7:30 a.m. EDT.
  • The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.
  • The company will issue a news release announcing financial results for the second quarter on July 27 prior to the conference call.
  • The replay will be available approximately one hour following the completion of the event.